Closed Joint Stock Company Biomedical Research and Production Complex Tsitomed (CJSC MBNPK Tsitomed) is a Russian pharmaceutical company specializing in drugs containing peptide compounds . Develops and manufactures medicines used in pediatrics, urology and dermatology. The company office is located in St. Petersburg . Production sites are located in St. Petersburg and Finland .
| CJSC MBNPK Citomed | |
|---|---|
 | |
| Base | 1989 |
| Location |
 Finland : Rauha |
| Key figures | Alexander Nikolaevich Khromov (General Director) |
| Industry | Pharmaceutical industry |
| Products | medicines |
| Website | www.cytomed.ru |
Content
- 1 History
- 2 Plant in St. Petersburg
- 3 Factory in Finland
- 4 notes
- 5 Links
History
The pharmaceutical company ZAO MBNPK Tsitomed was founded in 1989.
In 2012, the construction of the Cytomed Oy factory in Finland was completed . The volume of investments in the project amounted to about 15 million euros [1] .
In 2016, the construction of the plant in the Novoorlovskaya Special Economic Zone in St. Petersburg was completed and licensing of the new production site began. The volume of investment in the project at this stage is more than 1 billion rubles [2] .
Plant in St. Petersburg
Since 2008, the production site is located on Vasilievsky Island. The territory of production is 1.2 thousand square meters. m. The finished dosage forms are produced at the plant: syrup, powder, capsules, suppositories, spray, cream, as well as pharmaceutical substances : Timogen, Prostatilen, Imichimod, Zinc arginyl glycinate.
Since 2013, ZAO MBNPK Tsitomed has been building a new plant on a 0.75-hectare site in the Novoorlovskaya Special Economic Zone in the north of St. Petersburg . [ significance of fact? ]
Factory in Finland
In 2012, the construction of the Cytomed Oy factory in Finland was completed in the village of Rauha in the municipality of Lappeenranta . In 2013, the plant passed the first inspection by the Finnish Pharmaceutical Safety and Development Agency (Fimea) for compliance with EU Good Manufacturing Practice Rules (EU GMP) and received a license and a GMP certificate for capsule manufacturing [3] . Currently [ when? ] The plant produces the drug "Tsitovir-3." The company plans to transfer to the Finnish site the production of the drug Prostatilen [4] .
Notes
- ↑ "Cytomed" transferred the production of Russian medicines from St. Petersburg to Finland . www.dp.ru. Date of treatment August 4, 2017.
- ↑ Vasily Petrovsky. “Cytomed” invests in development - RIA AMI (AMI-TASS) . RIA AMI (May 20, 2015). Date of treatment August 4, 2017.
- ↑ The first Russian pharmaceutical factory opened in Finland (Rus.) , Yle Uutiset . Date of treatment August 4, 2017.
- ↑ The pharmaceutical company “Cytomed” expands its production in Lappeenranta (Russian) , Yle Uutiset . Date of treatment August 4, 2017.